Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Albino Petrone (Cosenza, Italy), Albino Petrone, Filippo Fimognari, Michela Quartieri, Giacomo Bruni. Effectiveness of glycopyrronium bromide in the treatment of small airways dysfunction. Eur Respir J 2016; 48: Suppl. 60, 4080

Member's Comments

No comment yet.

Related content which might interest you: Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Interaction between aclidinium bromide and formoterol fumarate in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Interaction between aclidinium bromide and formoterol fumarate; effects on human bronchial smooth muscle Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014 Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Efficacy of carbamazepine in treatment of bronchial asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide Source: International Congress 2015 – COPD: interesting notes Year: 2015 Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014